Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

The European Commission has approved two new indications for Keytruda (pembrolizumab), an anti-PD-1 therapy, in gynecologic cancers.

October 25, 2024

Vol.50 No.40

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

SU2C announces grants supporting research in six cancer types

Stand Up To Cancer announced grants to several teams of leading cancer investigators in support of cutting-edge research in a variety of cancers including head and neck, pediatric, pancreatic, breast, rectal, and gastro-esophageal cancers, as well as research focused on how the microbiome communicates with the immune system.

October 18, 2024

Vol.50 No.39

Regulatory News

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated as a first-line treatment for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted positive opinions recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, for two indications in gynecologic cancers.

September 27, 2024

Vol.50 No.36

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

YOU MAY BE INTERESTED IN

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

SU2C announces grants supporting research in six cancer types

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

Renew today!

Subscriber content

Login

Keytruda meets primary endpoint as perioperative treatment regimen in resected, locally advanced HNSCC

YOU MAY BE INTERESTED IN

EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

SU2C announces grants supporting research in six cancer types

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitorsVote may lead to rollback of some indications held by BMS and Merck

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

EU CHMP gives positive opinion to Keytruda for two types of gynecologic cancers

Login

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors
Vote may lead to rollback of some indications held by BMS and Merck

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications